ComplianceOnline

FDA Draft Guidance on Risk Information in Prescription Drug & Medical Device Ads, Promotional Labeling

  • By: www.fda.gov
  • Date: November 17, 2011
Webinar All Access Pass Subscription Abstract:

The FDA has issued a draft guidance document on how manufacturers should present risk information in promotional material and ads for prescription drugs and medical devices. It describes the factors that the agency takes into consideration when evaluating ads and promotional labeling for prescription drugs and medical devices.

Bookmark and Share

Trending Compliance Trainings

Trial Master File and Clinical Data Management Regulated by FDA
By - Carolyn Troiano
On Demand Access Anytime
Good Documentation Practice and Record Keeping Regulations (FDA & EMA)
By - Dr. Afsaneh Motamed Khorasani
On Demand Access Anytime
GAMP Data Integrity 21 CFR Part 11 Training Course
By - Kelly Thomas
On Demand Access Anytime
NEW Reclamation Process - Fed Gov't Payments
By - Donna K Olheiser
On Demand Access Anytime
Understanding and Preparing for FDA Pharmaceutical Inspections
By - Michael Ferrante
On Demand Access Anytime
How to conduct an effective BSA Audit
By - Justin Muscolino
On Demand Access Anytime
Installation and Qualification of the Packaging Lines
By - John E Lincoln
On Demand Access Anytime
Best Sellers
You Recently Viewed
    Loading